Small Animal Imaging Core Facility The goal of the Small Animal Imaging (SAI) core is to provide advanced animal imaging services, including imaging acquisition and image analysis tools that will facilitate cancer research at UNC and beyond. The imaging ability provided by the core allowed sophisticated monitoring of animal models, especially for studies focusing on cancer etiology and molecular therapeutics. The SAI core currently houses 10 imaging devices, including two 3T Siemens MR scanners, a 9.4T Bruker small animal MR scanner, a GE Explore animal PET/CT scanner, a UNC-designed high resolution SPECT scanner, a high resolution microCT for specimens (SCANCO), a high frequency ultrasound system (VisualSonics), and three IVIS optical imaging systems with capability for both bioluminescence and fluorescence imaging. Three additional imaging devices will be added to the SAI core in 2010: a GE SPECT/CT, a Fluorescence Molecular Tomography system, and a novel carbon nanotube-based CT. The SAI core currently supports 54 research projects. The SAI core requests $115,958 in CCSG funds, representing 12% its operating costs; 63% of the core's use is allocated to Cancer Center members. The increase in funding is requested to support the additional personnel and service contracts for new imaging equipment. For the next funding cycle, the SAI core proposes two major goals: expanding imaging, education and training services and developing multimodality imaging technology and analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-39
Application #
8786518
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
39
Fiscal Year
2015
Total Cost
$212,687
Indirect Cost
$73,406
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications